bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
bioAffinity Technologies announced a registered direct offering and a concurrent private placement expected to generate approximately $4 million in gross proceeds. The transaction terms include common stock (or pre-funded warrants) priced at $6.122 (or $6.115 per pre-funded warrant) and warrants for up to 980,072 shares exercisable after stockholder approval.